Induction chemotherapy with docetaxel, cisplatin, fluorouracil and I-leucovorin for locally advanced head and neck cancers: A modified regimen for Japanese patients

Anti-Cancer Drugs

Volumn 14, Issue 10, 2003, Pages 801-807

  Watanabe, Akihito ^a   Taniguchi, Masanobu ^a   Sasaki, Shigeyuki ^b  

^a KEIYUKAI SAPPORO HOSPITAL   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

Combination chemotherapy; Docetaxel; Japanese patient; Organ preservation; Squamous cell carcinoma of the head and neck

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG INFUSION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CARCINOMA; HUMAN; MALE; MEDICAL ASSESSMENT; NEUROPATHY; NEUTROPENIA; PRESERVATION; PRIORITY JOURNAL; RESPONSE TIME; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; VOMITING;

EID: 1542405224     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200311000-00005     Document Type: Article

References (29)

1. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med 1993; 328:184-194.
2. Catimel G. Head and neck cancer. Guidelines for chemotherapy. Drugs 1996; 51:73-88.
3. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer. Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 1996; 88:890-899.
4. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000; 355:949-955.
5. The Department of Veteran's Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-1690.
6. Spaulding MB, Fischer SG, Wolf GT. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 1994; 12:1592-1599.
7. Urba SG, Forastiere AA. Systemic therapy of head and neck cancer. Most effective agents, areas of promise. Oncology 1989; 3:79-88.
8. Clark JR, Busse PM, Norris Jr CM, Andersen JW, Dreyfuss Al, Rossi RM, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck. Long-term results. J Clin Oncol 1997; 15:3100-3110.
9. Schneider M, Etienne MC, Milano G, Thyss A, Otto J, Dassonville O, et al. Phase II trial of cisplatin, fluorouracil, and pure folic acid for locally advanced head and neck cancer: a pharmacokinetic and clinical survey. J Clin Oncol 1995; 13:1656-1662.
10. Catimel G, Verweij J, Mattijssen V, Hanauske A, Piccart M, Wanders J, et al. Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5:533-537.
11. Dreyfuss Al, Clark JR, Norris CM, Rossi RM, Lucarini JW, Busse PM, et al. Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996; 14:1672-1678.
12. Colevas AD, Busse PM, Norris CM, Fried M, Tishler RB, Poulin M, et al. Induction chemotherapy with docetaxel, cisplatin, fluorouracil, and leucovorin for squamous cell carcinoma of the head and neck: a phase I/II trial. J Clin Oncol 1998; 16:1331-1339.
13. Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, et al. Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck. J Clin Oncol 1999; 17:3503-3511.
14. Sobin LH, Wittekind CH. UICC TNM Classification of Malignant Tumors, 5th edn. New York: Wiley; 1997.
15. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
16. Ajani JA, Welch SR, Raber MN, Fields WS, Krakoff IH. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-159.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete objections. J Am Stat Ass 1958; 53:457-481.
18. Taguchi T, Furue H, Niitani H, Ishitani K, Kanamaru R, Hasegawa K, et al. Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug (in Japanese, abstract in English). Jpn J Cancer Chemother 1994; 21: 1997-2005.
19. Inuyama Y, Kataura A, Togawa K, Saijo S, Satake B, Takeoda S, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent head and neck cancer (in Japanese, abstract in English). Jpn J Cancer Chemother 1999; 26:107-116.
20. Ikeda K, Terashima M, Kawamura H, Takiyama I, Koeda K, Takagane A, et al. Pharmacokinetics of cisplatin in combined cisplatin and 5-fluorouracil therapy: a comparative study of three different schedules of cisplatin administration. Jpn J Clin Oncol 1998; 28: 168-175.
21. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after tree-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985; 55:1123-1128.
22. Fuwa N, Ito Y, Kodaira T, Matsumoto A, Kamata M, Furutani K, et al. Therapeutic results of alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: its usefulness and controversial points. Jpn J Clin Oncol 2001; 31:589-595.
23. Hareyama M, Sakata K, Shirato H, Nishioka T, Nishio M, Suzuki K, et al. A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma. Cancer 2002; 94:2217-2223.
24. Fujii M, Ohno Y, Tokumaru Y, Imanishi Y, Kanke M, Tomita T, et al. Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer. Support Care Cancer 2001; 9:366-371.
25. Nose H, Okada S, Okusaka T, Furuse J, Yoshino M, Ogoshi K, et al. 5-fluorouracil continuous infusion combined with cisplatin for advanced pancreatic cancer: a Japanese cooperative study. Hepatogastroenterology 1999; 46:3244-3248.
26. Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T, et al. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol 2002; 7:335-342.
27. Yano T, Koga T, Ninomiya S, Takeo S. Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues. Int J Clin Oncol 2002; 7:361-364.
28. Hamaji M, Nishida T, Miyazaki S, Nishida Y. Thymidine phosphorylase is correlated with DPD in colon cancer (in Japanese, abstract in English). Jpn J Cancer Chemother 2003; 30:495-500.
29. Shin DM, Glisson BS, Khuri FR, Lippman SM, Ginsberg L, Diaz Jr E, et al. Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck. Cancer 2002; 95:322-330.